BAFNAPHARM

Bafna Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on February 13, 2020.

Bafna Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended December 31, 2019.

Bafna Pharmaceuticals Limited has informed the Exchange regarding Board meeting held on February 13, 2020.

Bafna Pharmaceuticals Limited has submitted to the Exchange a copy of Details of Related party transactions In compliance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.

Bafna Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2019.

Bafna Pharmaceuticals Limited has informed the Exchange regarding Board meeting held on November 13, 2019.

The Exchange had sought clarification from Bafna Pharmaceuticals Limited for the quarter ended 30-Jun-2019 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is enclosed.

BAFNAPHARM: Members of the Exchange are hereby informed that the trading in Equity Shares of Bafna Pharmaceuticals Limited shall be suspended w.e.f. August 26, 2019 (i.e. closing hours of trading on August 23, 2019) on account of Reduction of Share Capital.

Bafna Pharmaceuticals Limited has informed the Exchange that the Company has fixed Record Date as August 27, 2019 for the purpose of determining the eligible equity shareholders whose equity shares shall stand reduced, pursuant to the Resolution Plan approved by the Hon��ble National Company Law Board Tribunal, Chennai Bench vide its Order dated 1st February, 2019 ("Approved Resolution Plan").

The Exchange has sought clarification from Bafna Pharmaceuticals Limited for the quarter ended 30-Jun-2019 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.

Bafna Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended June 30, 2019.

Bafna Pharmaceuticals Limited has informed the Exchange regarding Board meeting held on August 10, 2019.

Bafna Pharmaceuticals Limited has informed the Exchange about

Bafna Pharmaceuticals Limited has informed the Exchange about

Bafna Pharmaceuticals Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on Jun 27, 2019. Further, the company has informed the Exchange regarding voting results.

Bafna Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on Jun 27, 2019

Bafna Pharmaceuticals Limited has informed the Exchange regarding Disclosure under Regulation 23(9) of SEBI ( LODR) Regulations 2015-Details of Related Party transactions.

Bafna Pharmaceuticals Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on Jun 27, 2019

The Exchange had sought clarification from Bafna Pharmaceuticals Limited with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Financial results not signed by authorized signatory/ies The response of the Company is enclosed.

Bafna Pharmaceuticals Limited has informed the Exchange that the Company has fixed Book Closure from June 24, 2019 to June 27, 2019 for the purpose of AGM.

The Exchange has sought clarification from Bafna Pharmaceuticals Limited with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results not signed by authorized signatory/ies The response of the Company is awaited.

Bafna Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2019.

Bafna Pharmaceuticals Limited has informed the Exchange regarding Board meeting held on May 27, 2019.

The Promoter along with PAC has submitted to the Exchange a copy of Annual Disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares and Takeovers), Regulations, 2011 as on March 31, 2019.

Bafna Pharmaceuticals Limited has informed the Exchange about

Bafna Pharmaceuticals Limited has informed the Exchange regarding National Company Law Appellate Tribunal, New Delhi Order.

Bafna Pharmaceuticals Limited has informed the Exchange that this is in continuation of earlier intimation dated February 05,2019 regarding resolution plan which was approved by NCLT, Chennai vide its order dated February 01, 2019 under the Provisions of IBC, 2016. Pursuant to the Resolution Plan a capital reduction is proposed and the capital of the fully paid up equity shareholders shall be reduced to 10% and consequently the existing 2.36 Crores number of shares shall be reduced to 0.236 Crores.

Bafna Pharmaceuticals Limited has informed the Exchange regarding "Supervision of the Resolution Plan".

Bafna Pharmaceuticals Limited has informed the Exchange regarding Appointment of Mr Babulal Kamelsh Kumar as Non- Executive Independent Director of the company w.e.f. February 08, 2019.

Bafna Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended December 31, 2018.

Bafna Pharmaceuticals Limited has informed the Exchange regarding Board meeting held on February 08, 2019.

Bafna Pharmaceuticals Limited has informed the Exchange regarding Update on CIRP/NCLT Order approving Resolution Plan.

Bafna Pharmaceuticals Limited has informed the Exchange that Mr. Radhakrishnan Dharmarajan has been appointed as Resolution Professional (RP) and Mr. Gopalsamy Ganesh Babu has been relieved as IRP vide Order Passed by National Company Law Tribunal, Single Bench, Chennai dated October 11, 2018.

Bafna Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on November 13, 2018.We would like to inform you that the Board at its meeting held on today approved the un-audited financial results for the quarter / half year ending 30th September 2018. Please find attached the un-audited financial results for quarter / half year ending 30th September 2018 along with the Limited Review Report obtained from the statutory auditor of the Company.The meeting commenced at 3.00 PM and concluded at 6.45 P.M

Bafna Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2018.

Bafna Pharmaceuticals Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 29, 2018. Further, the company has informed the Exchange regarding voting results.

Bafna Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 29, 2018

Bafna Pharmaceuticals Limited has informed the Exchange that the Register of Members & Share Transfer Books of the Company shall remain closed from September 23, 2018 to September 29, 2018 (both days inclusive) for the purpose of Annual General Meeting scheduled to be held on September 29, 2018.

Bafna Pharmaceuticals Limited has informed the Exchange regarding Resignation of Mr R DWARKANATHAN as Non- Executive Independent Director of the company w.e.f. August 21, 2018.

Bafna Pharmaceuticals Limited has informed the Exchange regarding Board meeting held on September 05, 2018.

Bafna Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended June 30, 2018.

Bafna Pharmaceuticals Limited has informed the Exchange regarding Board meeting held on August 13, 2018.

The Exchange had sought clarification from Bafna Pharmaceuticals Limited with respect to announcement dated regarding Disclosure pursuant to Regulation 30 of SEBI ( Listing Obligations and Disclosure Requirements) Regulations, 2015.On basis of above the Company is required to clarify following:1. Any other material information not involving commercial secrets2. Salient features, not involving commercial secrets, of the resolution plan approved by the Tribunal, in such form as may be specified3. Approval of resolution plan by the Tribunal or rejection, if applicable4. Filing of resolution plan

BAFNAPHARM:The Exchange has sought clarification from Bafna Pharmaceuticals Limited with respect to announcement dated 18-Jul-2018, regarding " Bafna Pharmaceuticals Limited has informed the Exchange regarding 'Disclosure pursuant to Regulation 30 of SEBI ( Listing Obligations and Disclosure Requirements) Regulations, 2015.'.". On basis of above the Company is required to clarify following: 1. Any other material information not involving commercial secrets<br> 2. Salient features, not involving commercial secrets, of the resolution plan approved by the Tribunal, in such form as may be specifi

Bafna Pharmaceuticals Limited has informed the Exchange regarding 'Disclosure pursuant to Regulation 30 of SEBI ( Listing Obligations and Disclosure Requirements) Regulations, 2015.'.

The Exchange had sought clarification from Bafna Pharmaceuticals Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Standalone Reconciliation of profit and loss not submitted -2. The company has not submitted the Statement of Modified Opinion or in case of unmodified opinion(s), a declaration to that effect to the Stock Exchange. The response of the Company is enclosed.

The Exchange has sought clarification from Bafna Pharmaceuticals Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone Reconciliation of profit and loss not submitted -2. The company has not submitted the Statement of Modified Opinion or in case of unmodified opinion(s), a declaration to that effect to the Stock Exchange. The response of the Company is awaited.

Bafna Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2018.

Bafna Pharmaceuticals Limited has informed the Exchange regarding Appointment of Mr Jitendra Pal as Company Secretary & Compliance Officer of the company w.e.f. May 28, 2018.

Bafna Pharmaceuticals Limited has informed the Exchange regarding Resignation of Mr Nirav Vikram Maniar as Non- Executiv Independent Director of the company w.e.f. May 28, 2018.